Lung Cancer – Expert Insights from Rachel Sanborn

Expert Interview

Dr Sanborn shares her ASCO21 highlights for lung cancer focusing on the outcomes of the use of anti-PD-(L)1 therapy in combination with chemotherapy versus immunotherapy in patients with advanced NSCLC (abstract 9001), results from the phase II CodeBreak 100 trial of sotorasib in pretreated KRASG12C-mutated NSCLC (abstract 9003) and provides an update from the PACIFIC trial (abstract 8511).
Interviewee: Rachel Sanborn
Affiliation(s): Co-Director, Thoracic Oncology Program; Director, Phase I Clinical Trials Program, Earle A. Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA
Disclosures: Honoraria: Amgen, AstraZeneca; Consulting or Advisory Role: AstraZeneca, Blueprint Medicines, Daiichi Sankyo/Lilly, EMD Serono, Genentech/Roche, Janssen Oncology, Macrogenics; Research Funding: AstraZeneca, Bristol-Myers Squibb (Inst), MedImmune (Inst), Merck; Travel, Accommodations, Expenses: AstraZeneca
Interview Date: June 10, 2021
Disclaimer: Springer Healthcare selected the experts for interview. The expert interviews appearing herein were not prepared or reviewed by ASCO and have not been subject to a peer review process. The ideas and opinions expressed herein do not necessarily reflect those of ASCO. ASCO assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the material contained in this publication or to any errors or omissions. Read full disclaimer here.
Share:
Share on facebook
Share on twitter
Share on linkedin

Abstracts Referenced In This Expert Interview

Oral Abstract Session

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis

Presenter: Oladimeji Akinboro, MD, MPH
Presentation Date: June 4, 2021
Abstract Number: 9001
Oral Abstract Session

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer

Presenter: Ferdinandos Skoulidis, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9003
Poster Session

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial

Presenter: David R. Spigel, MD, FASCO
Presentation Date: June 4, 2021
Abstract Number: 8511

Other Lung Cancer Content

Expert Interview

Lung Cancer – Expert Insights

Dr Goto shares discusses the safety and efficacy findings of the phase 1 clinical trial of patritumab deruxtecan (HER3-DXd), a HER3-directed antibody-drug conjugate, in patients with advanced EGFR-mutant NSCLC (abstract 9007). He also highlights the results from the phase 3 IMPACT trial of adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with phase 2-3 EGFR-mutated NSCLC (abstract 8501).
Interviewee: Yasushi Goto, MD
Interview Date: June 11, 2021
Expert Interview

Lung Cancer – Expert Insights

Dr Wakelee discusses her ASCO21 highlights for lung cancer, including results from the phase III global IMpower010 study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected NSCLC (abstract 8500), findings from a pooled analysis of eight randomized controlled trials to evaluate the use of anti-PD(L1) therapy in combination with chemotherapy versus immunotherapy for 1L treatment of advanced NSCLC with PD-L1 score 1-49% (abstract 9001), and results of the OS and exploratory subgroup analyses from the phase 2 CodeBreak 100 trial evaluating sotorasib in pretreated KRAS p.G21c mutated NSCLC (abstract 9003).
Interviewee: Heather A. Wakelee, FASCO, MD
Interview Date: June 9, 2021
Expert Interview

Lung Cancer – Expert Insights

Dr Reck discusses his ASCO21 highlights on non-small cell lung cancer, including updates on nivolumab plus ipilimumab at 4 years from CheckMate 227 (abstract 9016) and at 2 years from CheckMate 9LA (abstract 9000), and phase 2 trial data from KEYNOTE-799 for the novel combination of pembrolizumab plus platinum chemotherapy and radiotherapy (abstract 8512).
Interviewee: Martin Reck, MD, PhD
Interview Date: June 7, 2021
Oral Abstract Session

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC)

Presenter: Heather A. Wakelee, FASCO, MD
Presentation Date: June 6, 2021
Abstract Number: 8500
Oral Abstract Session

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial

Presenter: Hirohito Tada, MD
Presentation Date: June 6, 2021
Abstract Number: 8501
Oral Abstract Session

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA

Presenter: Martin Reck, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9000
Oral Abstract Session

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis

Presenter: Oladimeji Akinboro, MD, MPH
Presentation Date: June 4, 2021
Abstract Number: 9001
Oral Abstract Session

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreaK 100 trial evaluating sotorasib in pretreated KRAS p.G12C mutated non-small cell lung cancer

Presenter: Ferdinandos Skoulidis, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9003
Oral Abstract Session

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, EGFR-mutated (EGFRm) non-small cell lung cancer (NSCLC)

Presenter: Pasi A. Janne, MD, PhD
Presentation Date: June 4, 2021
Abstract Number: 9007
Poster Session

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial

Presenter: David R. Spigel, MD, FASCO
Presentation Date: June 4, 2021
Abstract Number: 8511
We'd love your feedback!
We'd love your feedback!

Welcome to ASCO Direct™

2021 Annual Meeting Highlights

Expert insights into key ASCO21 data that will impact clinical practice and patient care plus complimentary access to 50 official ASCO video presentations and downloadable slides, picked by our Experts.

ASCO Direct is an officially licensed program of the American Society of Clinical Oncology® (ASCO®)

This program is supported by Bristol Myers Squibb and brought to you by Springer Healthcare